logo
logo

Acrigen Biosciences Raises Seed Financing To Advance Precision Gene Editing Technology And Therapeutic Pipeline

Sep 28, 2021•almost 4 years ago

Round Type

seed

Berkeley

Description

Acrigen Biosciences, Inc. (“Acrigen”), an early-stage biotechnology company developing precision gene editing technology and genetic medicines, today announced its seed financing round led by Red Tree Venture Capital with participation from Alexandria Venture Investments, the Berkeley Catalyst Fund, Dolby Family Ventures, and biotechnology entrepreneur investors. The capital will be used to advance Acrigen’s therapeutic pipeline toward the clinic and accelerate research and development of novel precision editing systems. Heath Lukatch, PhD, founder and managing partner at Red Tree Venture Capital, will join Acrigen’s Board of Directors.

Company Information

Company

Acrigen Biosciences

Location

Berkeley, California, United States

About

Acrigen Biosciences is an early-stage life science gene editing company based in Berkeley, California. We are building a pipeline of therapies to treat genetic disorders using our proprietary precision gene editing technology. Our technology utilizes novel CRISPR-Cas gene editors coupled with anti-CRISPR proteins to improve the precision, efficacy, and safety of genetic therapies. The company was co-founded in 2019 by Dr. Joseph Bondy-Denomy (Associate Professor at UCSF and discoverer of anti-CRISPR proteins) and Dr. David Rabuka (former Founder and CSO of Redwood Bioscience) with the mission of bringing precision genetic therapies to patients. For more information, go to www.acrigen.com.